Uraemia
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged between 18 and 65; 2. ASA physical status score: III–IV; 3. BMI 18.5–30.0 kg/m^2; 4. Performed the first kidney transplant; 5. No severe dysfunction of vital organs such as the heart, lungs or liver; 6. No neurological disorders or mental health issues; 7. No history of allergy to disodium propofol or propofol.
Exclusion criteria
Exclusion criteria: 1. Participants who do not consent to participate in this study; 2. Patients with a known allergy to disodium propofol, propofol or related components; 3. Patients with suspected difficult airway or intubation difficulties; 4. Patients with concomitant dysfunction of vital organs such as the heart, lungs, brain or liver; 5. Pregnant or breastfeeding women; 6. Patients with a history of substance abuse or dependence on long-term sedatives, hypnotics or opioids; 7. Patients requiring modification of the anesthetic plan or a change in surgical approach due to surgery-related factors; 8. Patients who have participated in other drug clinical trials within the past three months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Observation of loss of consciousness in kidney transplant recipients following administration of a predetermined dose of disodium propofol;The correlation between ED95 during general anaesthesia-induced sedation in kidney transplant recipients and serum alkaline phosphatase levels.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Record the time at which sedation was achieved and the incidence of adverse reactions in patients;On admission, prior to induction, 1 minute before intubation, and after intubation: blood pressure, heart rate and BIS.; | — |
Countries
China
Contacts
The First Affiliated Hospital of University of Science and Technology of China